Cargando…

Evaluation of (18)F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy

PURPOSE: Prostate-specific membrane antigen (PSMA) ligands targeting has shown promising results in staging of prostate cancer (PCa). The aim of present study was to evaluate the value of (18)F-PSMA-1007 PET/CT in PCa patients with biochemical recurrence. METHODS: 71 patients with PCa after radical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Xing, Jiang, Xiao, Liu, Luzhou, Wang, Xiaoxiong, Li, Chuan, Yao, Yutang, Kou, Ying, Shen, Jiaqi, Shen, Taipeng, Li, Zeng, Yang, Shengke, Zhou, Shukui, Liao, Hong, Luo, Zhifu, Wu, Xiaoai, Chen, Shirong, Cheng, Zhuzhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633368/ https://www.ncbi.nlm.nih.gov/pubmed/34837847 http://dx.doi.org/10.1016/j.tranon.2021.101292

Ejemplares similares

Intra-Individual Comparison of 18F-PSMA-1007 and 18F-FDG PET/CT in the Evaluation of Patients With Prostate Cancer
por: Zhou, Xing, et al.
Publicado: (2021)

FAPI-04 PET/CT Using [(18)F]AlF Labeling Strategy: Automatic Synthesis, Quality Control, and In Vivo Assessment in Patient
por: Jiang, Xiao, et al.
Publicado: (2021)

An exploratory study of unexplained concentration of (18)F-PSMA-1007 in the bladder for prostate cancer PET/CT imaging
por: Dang, Jun, et al.
Publicado: (2023)

Quick Automatic Synthesis of Solvent-Free 16α-[(18)F] Fluoroestradiol: Comparison of Kryptofix 222 and Tetrabutylammonium Bicarbonate
por: Jiang, Xiao, et al.
Publicado: (2020)

Detection Efficacy of (18)F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
por: Giesel, Frederik L., et al.
Publicado: (2019)

Trichostatin A reverses epithelial-mesenchymal transition and attenuates invasion and migration in MCF-7 breast cancer cells
por: Wang, Xiaoxiong, et al.
Publicado: (2020)

False Positive Findings of [(18)F]PSMA-1007 PET/CT in Patients After Radical Prostatectomy with Undetectable Serum PSA Levels
por: Orevi, Marina, et al.
Publicado: (2022)

(18)F-PSMA-1007 PET in Biochemical Recurrent Prostate Cancer: An Updated Meta-Analysis
por: Ferrari, Matteo, et al.
Publicado: (2021)

Diagnostic accuracy of [(18)F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer
por: Mingels, Clemens, et al.
Publicado: (2022)

The prognostic value of (18)F-PSMA-1007 PET/CT in predicting pathological upgrading of newly diagnosed prostate cancer from systematic biopsy to radical prostatectomy
por: Zheng, Anqi, et al.
Publicado: (2023)

Diagnostic performance of (18)F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer
por: Rahbar, Kambiz, et al.
Publicado: (2018)

Performance of (18) F-FAPI PET/CT in assessing glioblastoma before radiotherapy: a pilot study
por: Yao, Yutang, et al.
Publicado: (2022)

Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy
por: Schmidt-Hegemann, Nina-Sophie, et al.
Publicado: (2018)

Prediction of Biochemical Recurrence After Radical Prostatectomy Based on Preoperative (68)Ga-PSMA-11 PET/CT
por: Qiu, Xuefeng, et al.
Publicado: (2021)

PSMA-Positive Low Malignant Gastrointestinal Stromal Tumor in the Stomach on F-18-PSMA-1007 PET/CT
por: Iversen, Peter, et al.
Publicado: (2022)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

High detection rate in [(18)F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients
por: Watabe, Tadashi, et al.
Publicado: (2021)

Peering through the PSMA PET Lens: The Role of the European Association of Urology Biochemical Recurrence Risk Groups after Radical Prostatectomy
por: Leplat, Charles, et al.
Publicado: (2023)

Predictors of PSMA PET Positivity: Analysis in a Selected Cohort of Biochemical Recurrence Prostate Cancer Patients after Radical Prostatectomy
por: Mapelli, Paola, et al.
Publicado: (2023)

Diagnostic Accuracy of (18)F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence
por: Sprute, Katharina, et al.
Publicado: (2021)

Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy
por: Bashir, Usman, et al.
Publicado: (2019)

(18)F-PSMA-1007 PET/CT uptake in multiple angiolipomas caused by PSMA expression in capillaries: a case report
por: Wang, Long, et al.
Publicado: (2021)

Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy
por: Roberts, Matthew J., et al.
Publicado: (2022)

Non-prostate uptake on (18)F-PSMA-1007 PET/CT: a case of myeloma
por: Veerasuri, Sowmya, et al.
Publicado: (2020)

Dose-reduced [(18)F]PSMA-1007 PET is feasible for functional imaging of the renal cortex
por: Valind, Kristian, et al.
Publicado: (2021)

Biokinetics and dosimetry of (18)F‐PSMA‐1007 in patients with prostate cancer
por: Hvittfeldt, Erland, et al.
Publicado: (2022)

Skeletal (18)F-PSMA-1007 uptake in prostate cancer patients
por: Janssen, Jorinde, et al.
Publicado: (2023)

Protocol for SNOTOB study: radical prostatectomy without prostate biopsy following (18)F-PSMA-1007 PET/CT based on a diagnostic model: a single-centre, single-arm, open-label study
por: Wang, Changming, et al.
Publicado: (2023)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI
por: Zhang, Yan-Nan, et al.
Publicado: (2022)

Preclinical comparative study of [(18)F]AlF-PSMA-11 and [(18)F]PSMA-1007 in varying PSMA expressing tumors
por: Piron, Sarah, et al.
Publicado: (2022)

Optimization of [(18)F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer
por: Trägårdh, Elin, et al.
Publicado: (2020)

Frequency and intensity of [(18)F]-PSMA-1007 uptake after COVID-19 vaccination in clinical PET
por: Maurer, Alexander, et al.
Publicado: (2022)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

(68)Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – diagnostic performance and impact on therapeutic decision-making
por: Grubmüller, B., et al.
Publicado: (2017)

PSMA-1007 Uptake in Ganglia of the Sympathetic Trunk and Its Intra-individual Reproducibility
por: Mamlins, E., et al.
Publicado: (2022)

Very Low Prostate PET/CT PSMA Uptake May Be Misleading in Staging Radical Prostatectomy Candidates
por: Rosenzweig, Barak, et al.
Publicado: (2022)

Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy
por: Rogowski, Paul, et al.
Publicado: (2021)

Diagnostic performance of 99mTc-HYNIC-PSMA SPECT/CT for biochemically recurrent prostate cancer after radical prostatectomy
por: Li, Bo, et al.
Publicado: (2022)

(18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
por: Giesel, Frederik L., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ahe4nc7sj6pqabai5ppho2u4f5